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Introduction: To assess clinical features of bronchioloalveolar
carcinoma (BAC) based on the 1999 World Health Organization
Classification (“pure BAC”), compare patients with pure BAC with
patients previously diagnosed as BAC not meeting the 1999 defini-
tion, and compare survival changes of pure BAC based on the old
and new (2009) staging systems.
Methods: A pulmonary pathologist reviewed each BAC tumor diag-
nosed between January 1, 1997, and December 31, 2007, identifying
cases meeting the new criteria. Cases were restaged according to the
seventh edition of the tumor, node, metastasis classification introduced
in 2009. Patients with pure BAC were analyzed under both staging
systems for changes in overall survival estimation.
Results: Of 338 total patients who were diagnosed with BAC, 117
were classified as pure and 221 were non-pure BAC. Seventy-eight
of the 117 and 178 of the 221 had no other primary lung cancer.
One-year and 5-year survival for the 78 patients with pure BAC
were 94.8 and 83.5%, and for the 178 patients were 92.6 and 46.4%,
respectively. Restaging for pure BAC cases resulted in nine of the 78
cases (12%) changing stage. Compared with the old staging, patients
with advanced stage under the new stage had a worse 5-year survival
(53% versus 45%), but no change was observed for stage IA.
Conclusions: For patients with pure BAC, the new pathologic system
favorably affects survival and the new staging system may more
accurately reflect prognosis in advanced stage cancer. Our results have
important implications for researchers, clinicians, and patients.
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The description of disease consistent with bronchioloal-veolar carcinoma (BAC) dates back to the 1800s. The
reported incidence of BAC in the literature has ranged
from 4 to 29% of non-small cell lung cancer (NSCLC)
cases.1,2 Lack of precision in prevalence and survival
estimates relates to wide variations in criteria distinguish-
ing BAC from adenocarcinoma.1–3
In 1999, the World Health Organization (WHO) Clas-
sification of Lung Tumors established strict criteria for BAC
diagnosis restricting it to tumors demonstrating pure bronchi-
oloalveolar growth pattern with no stromal, lymphatic, or
vascular invasion.4 Our current understanding of BAC is
based on data reported before publication of the 1999 WHO
Classification or more recent studies, which did not include
central pathologic review of all cases using the WHO Clas-
sification. In addition, the International Association for the
Study of Lung Cancer has revised the lung cancer staging
system.5 The impact of the definition and staging changes on
the epidemiology of BAC has not been clearly defined.
The goals of this study were to: (1) assess the clinical
features of BAC based on the 1999 WHO Classification; (2)
compare these patients with patients previously diagnosed as
BAC but not currently meeting the 1999 WHO Classification;
(3) compare the survival change of BAC based on the old and
new staging system. Cases received diagnosis and/or treat-
ment at Mayo Clinic in Rochester, Minnesota, during the
11-year period between January 1, 1997, and December 31,
2007.
MATERIALS AND METHODS
Study Cohort
Only patients who provided informed consent as ap-
proved by the Mayo Clinic Institutional Review Board were
included in this study. Patients were ascertained daily from a
computerized pathology reporting system that identified all
lung cancer cases who received care in our institution.
Clinical data was abstracted from medical records for
each patient during a baseline visit at the time of diagnosis
and included demographics, history of tobacco exposure,
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alcohol use, family cancer history, comorbid medical condi-
tions, and lung cancer histology, staging, and treatment.
Clinical staging was assigned by results from available chest
radiography, computed tomography, bone scans, positron
emission tomography scans, and magnetic resonance imag-
ing. If a patient received any type of diagnostic procedure or
therapy elsewhere, authorization for the release of medical
information and copies of relevant medical records were
requested. Tobacco use history included age of regular smok-
ing initiation, average cigarettes smoked per day, total years
smoked, and other types of tobacco products used. Never
smokers were defined by self-report as having smoked less
than 100 cigarettes during their lifetime. Former smokers
were defined as reporting at least 6 months of smoking
abstinence at the time of diagnosis. Current smokers were
daily cigarette smokers or those who smoked within 6 months
of the time of diagnosis.
The vital status of each patient was verified through the
Mayo Clinic registration database, next-of-kin reports, death
certificates and obituary documents, the Mayo Clinic Tumor
Registry, and the Social Security Death Index internet site.
Vital status information for all patients in the lung cancer
cohort is updated at the beginning of each calendar year.
Clinical information was obtained from the most recent
clinical note or the last mailed study questionnaire. The
mailed study questionnaire obtained information on new
diseases and treatments that occurred after the initial diagno-
sis. For deceased patients, a follow-up packet was sent to the
next-of-kin to obtain proxy information.
Histopathology Re-Review
A review of histologic slides of surgically resected
specimens was required to make a diagnosis of BAC. A
pulmonary pathologist on our investigative team (M.C.A.)
reviewed tumor slides for each tumor diagnosed as BAC and
identified cases that met criteria for diagnosis of BAC ac-
cording to the 1999 and 2004 WHO Classification.6 A tumor
was adjudicated as BAC if it was an adenocarcinoma that
demonstrated a pure bronchioloalveolar growth pattern with
no lymphatic, vascular, or pleural invasion, and no distortion
of alveolar architecture. Tumors initially classified as BAC
no longer meeting the new WHO classification were labeled
as “non-pure” BAC to contrast with the “pure” BAC tumors.
Tumors previously diagnosed as BAC on the basis of cytol-
ogy or needle biopsy specimens were excluded from this
study. Recorded histologic descriptors of each tumor in-
cluded histologic subtype (mucinous or non-mucinous) and
presence of scar.
Lung Cancer Staging and Restaging
All patients were staged at the time of enrollment by the
sixth edition of the tumor, node, metastasis (TNM) classifi-
cation for Malignant Tumors introduced in 2002. The patients
were then restaged by the seventh edition of the TNM
classification of Malignant Tumors introduced in 2009. The
2009 TNM classification includes additional cutoffs for tu-
mor size subgrouping T1 into T1a (2 cm) and T1b (2 cm
but 3 cm), T2 into T2a (3 cm but 5 cm) and T2b (5
cm but 7 cm), and reclassifying tumors 7 cm to T3.7
Moreover, the 2009 staging system reclassifies satellite le-
sions in the same lobe from T4 to T3 and reclassifies addi-
tional nodules in another ipsilateral lobe from M1 to T4.7
Pleural effusion is reclassified from T into M1 category.7
Statistical Analysis
We compared clinical characteristics and outcomes of
two groups of patients identified after review of histopathol-
ogy of all patients who received a diagnosis of BAC: (1)
patients who met the 1999 WHO criteria for BAC (pure
BAC); and (2) patients who did not meet the criteria were
termed (non-pure BAC). Descriptive analyses were con-
ducted on patient characteristics, clinical features of disease,
and clinical outcomes. All statistical tests used were two-
sided with an alpha  0.05 significance threshold. Compar-
ative analyses to identify differences in patient and disease
characteristics at baseline were performed using 2 tests or
Fisher exact test tests (for sparse tables) on categorical
variables and Kruskal-Wallis tests on continuous variables.
Similar tests were also conducted to identify differences
based on histologic subtype.
Survival was defined as the time from BAC diagnosis
to death or date the patient was last reported to be alive.
Patients known to be alive at the last contact were censored.
The Kaplan-Meier method was used to create survival curves
and to estimate survival at yearly increments. Overall sur-
vival differences in gender, age at diagnosis, smoking status,
histologic subtype, stage of disease, history of other cancer
(excluding nonmelanoma skin cancer), and presence of
symptoms were assessed for statistical significance by the
log-rank test. Differences in survival at 1 year were calcu-
lated by censoring all deaths that occurred after 1 year.
Similarly, differences in survival at 5 years and 10 years were
calculated by censoring all deaths that occurred after 5 years
and 10 years, respectively. Multivariable Cox proportional
hazards models were constructed to estimate the relative risk
of mortality using the predetermined predictors of age at
diagnosis, gender, smoking status, and presence of symptoms
at presentation.
RESULTS
Between January 1, 1997, and December 31, 2007, 338
patients were diagnosed with BAC. Of these, 117 were
classified as pure BAC by the 1999/2004 WHO definition and
221 were classified as non-pure BAC. Of the 117 patients
with pure BAC, 78 had no other non BAC lung cancer.
The mean age at diagnosis of the 78 patients with pure
BAC was 66 years, 68% were women and 28% were never
smokers (Table 1). Seventeen percent had a family history of
lung cancer among first degree relatives and 65% had a family
history of other cancers among first degree relatives. Five per-
cent had another BAC primary (Table 2). Eighteen percent were
mucinous type (Table 3). No significant differences were ob-
served between males and females with respect to treatments
received (Table 3). The 1-year survival rate was 94.8% (95%
confidence interval [CI], 90.0–99.9%), and the 5-year survival
rate was 83.5% (95% CI, 74.9–93.1%) (Table 4).
Of the 221 patients with non-pure BAC, 178 had no
other non-BAC lung cancer and would have been classified as
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BAC before the use of 1999 WHO definition. Compared with
the 78 patients with pure BAC, a greater percentage of the
178 patients with non-pure BAC were diagnosed at 75 years
of age and older, were more likely to be male, had no family
history of other cancers in first degree relatives (Table 1), and
had higher grade and stage tumors (Table 2). Both the
one-year survival rate of 86.7% (95% CI, 81.8–91.9%) and
the 5-year survival rate of 46.4% (95% CI, 38.9–55.3%) were
remarkably lower (p  0.0618 for 1 year and p  0.0001 for
5 year) than patients with pure BAC (Table 4).
Impact of the New Staging System
When the 78 pure BAC cases were restaged in accor-
dance with the seventh edition of the TNM classification of
Malignant Tumors, the assigned stage changed for nine cases
(12%), a change occurred from IB to IIA for three cases, IIIB
to IIB for two cases, and IV to IIIA for four cases.
Among the 78 pure BAC cases, based on the old
staging system, patients with stage IIIB/IV had significantly
worse survival than those with stage IA (Figure 1, Panel A).
On the basis of the 2009 staging system, patients with stage
IIIA/IV had significantly worse survival than patients with
stage IA (Figure 1, Panel B). No differences were observed in
survival between non-mucinous and mucinous histologies
under either staging system (Figure 2).
DISCUSSION
Important findings from this study are (1) use of the
1999 WHO definition to re-review 338 BACs diagnosed at
TABLE 1. Comparison of Patients with Pure and Non-Pure Bronchioloalveolar Carcinoma with
no Other Non-BAC Lung Cancer
Pure BAC
(N  78)
Non-Pure BAC
(N  178)
Total
(N  256) pa
Age at diagnosis 0.0540b
Mean (SD) 65.9 (9.61) 67.9 (12.27) 67.3 (11.54)
Median 67.0 69.0 69.0
Q1, Q3 61.0, 73.0 62.0, 76.0 61.5, 75.0
Age at diagnosis 0.0438
55 12 (15.4%) 26 (14.6%) 38 (14.8%)
56–74 53 (67.9%) 96 (53.9%) 149 (58.2%)
75 13 (16.7%) 56 (31.5%) 69 (27%)
Gender 0.0099
Female 53 (67.9%) 90 (50.6%) 143 (55.9%)
Male 25 (32.1%) 88 (49.4%) 113 (44.1%)
Race 0.1510
Missing 0 (—) 8 (—) 8 (—)
Non-whitec 8 (10.3%) 9 (5.3%) 17 (6.9%)
White 70 (89.7%) 161 (94.7%) 231 (93.1%)
Smoking status at diagnosis 0.8704
Never smokers 22 (28.2%) 56 (31.5%) 78 (30.5%)
Former smokers 41 (52.6%) 90 (50.6%) 131 (51.2%)
Current smokers 15 (19.2%) 32 (18%) 47 (18.4%)
Pack-years (ever smokers) 0.2376
Missing 0 (—) 17 (—) 17 (—)
0–20 17 (30.4%) 30 (28.6%) 47 (29.2%)
21–40 22 (39.3%) 30 (28.6%) 52 (32.3%)
41–60 11 (19.6%) 21 (20%) 32 (19.9%)
60 6 (10.7%) 24 (22.9%) 30 (18.6%)
SHS exposure (never smokers) 0.9900
Missing 5 (—) 18 (—) 23 (—) 1.0000d
Not exposed 4 (23.5%) 9 (23.7%) 13 (23.6%)
Exposed 13 (76.5%) 29 (76.3%) 42 (76.4%)
Family history of lung cancer (1st degree) 0.7612
No 65 (83.3%) 151 (84.8%) 216 (84.4%)
Yes 13 (16.7%) 27 (15.2%) 40 (15.6%)
Family history of other cancer (1st degree) 0.0044
No 27 (34.6%) 96 (53.9%) 123 (48%)
Yes 51 (65.4%) 82 (46.1%) 133 (52%)
a All p values are from 2 tests unless otherwise noted.
b Kruskall-Wallis test.
c Non-white includes Alaskan/Native American, Black, Asian/Pacific Islander, and other unspecified races.
d Fisher exact test.
SHS, secondhand smoke; SD, standard deviation; BAC, bronchioloalveolar carcinoma.
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Mayo Clinic, Rochester, between 1997 and 2007 resulted in
only 117 (35%) meeting the new criteria; (2) patients with
pure BAC by the 1999 definition had a greater 5-year survival
(83.5%) compared with the patients with BAC under the old
definition (46.4%); and (3) the 2009 staging system better
distinguished between early versus late stage BAC with
5-year survival at 88.5% versus 45.0%, respectively.
We observed a mean age of 65.9  9.6 years among
patients with pure BAC at the time of diagnosis, and the mean
age of patients with BAC in the Surveillance, Epidemiology,
and End Results (SEER) database has been reported to be
67.1 years.8 In a study of the association between age and
NSCLC among 293,427 incident cases of NSCLC in the
SEER database from 1973 to 2002, the mean age of 13,859
patients with BAC was 66.99 10.66 years.9 A multivariable
analysis of the SEER data showed that patients with BAC
were more likely to be female (adjusted odds ratio 2.06, 95%
CI, 1.99–2.14), and we observed that almost two-thirds of
pure BAC cases were women. Although the SEER data is
limited by the inability to confirm the diagnosis of BAC by
independent pathologists, our findings relating to gender and
age in patients with BAC are similar.
We observed higher 1- and 5-year survival rates (94.8
and 83.5%, respectively) among the patients with pure BAC
identified in our cohort than has been reported previously. In
a study analyzing data from the population-based Cancer
Surveillance Programs of three Southern California counties
from 1995 to 2003, survival for patients with BAC was
69.6% at 1 year and 41.4% at 5 years.10 The investigators
concluded that the observed survival benefit likely reflects
changes in the revised 1999 WHO classification. However,
the study did not involve central pathologic review of all
cases and included BAC cases from different institutions in
the three Southern California counties. Further, it is unlikely
that the 1999 classification was uniformly applied by clinical
pathologists immediately after publication of the new WHO
classification and that the cases of BAC diagnosed after 1999
were indeed pure BAC as established by the 1999 WHO
classification.
Our observation that 59% of patients with pure BAC had
no symptoms present at the time of diagnosis is also consistent
with previous investigations. In a study of 274 patients with
NSCLC undergoing surgical resection, patients with incidentally
detected lung cancer were three times as likely to have BAC
histology.11 Among patients who received a baseline computed
tomography scan in the Early Lung Cancer Action Project,
(ELCAP) more than two-thirds had BAC histology.12 Our study
TABLE 2. Comparison of Disease Characteristics Between Patients with Pure and Non-Pure
Bronchioloalveolar Carcinoma with no Other Non-BAC Lung Cancer
Pure BAC
(N  78)
Non-Pure BAC
(N  178)
Total
(N  256) pa
Grade 0.0006
Well differentiated 78 (100) 148 (83.1) 226 (88.3) 0.0001b
Moderately differentiated 0 (0) 14 (7.9) 14 (5.5)
Nongradable and missing 0 (0) 16 (9.0) 16 (6.3)
Stage (old) 0.0001
Missing 0 (—) 7 (—) 7 (—)
IA 61 (78.2) 70 (40.9) 131 (52.6)
IB 7 (9) 36 (21.1) 43 (17.3)
II/IIIA 0 (0) 14 (8.2) 14 (5.6)
IIIB/IV 10 (12.8) 51 (29.8) 61 (24.5)
Tumor (old) 0.0001
Missing 0 (—) 9 (—) 9 (—)
T1 63 (80.8) 76 (45.0) 139 (56.3)
T2 10 (12.8) 52 (30.8) 62 (25.1)
T3–4c 5 (6.4) 21 (12.4) 26 (10.5)
Not assessable 0 (0) 20 (11.8) 20 (8.1)
Multiple BACd primaries 0.8252
No 74 (94.9) 170 (95.5) 244 (95.3) 0.7595b
Yes 4 (5.1) 8 (4.5) 12 (4.7)
Recurrence/progression of BACd 0.3003
No 72 (92.3) 170 (95.5) 242 (94.5) 0.3706b
Yes 6 (7.7) 8 (4.5) 14 (5.5)
The values in the parenthesis are given in percentage.
a All p values are from 2 tests unless otherwise noted.
b Fisher exact test.
c All five patients with pure BAC and 19 non-pure BAC cases were T4. The remaining two patients with non-pure BAC were T3, one
due to lung atelectasis and one due to satellite nodules in the same lobe.
d BAC defined as any current BAC diagnosis for the pure BAC group, defined as an ever diagnosis of BAC for the non-pure BAC group.
BAC, bronchioloalveolar carcinoma.
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TABLE 3. Comparison of Disease Characteristics, Comorbidities, Symptoms and Performance Status, and Treatment Between
Male and Female Patients with Pure Bronchioloalveolar Carcinoma and no Other Non-BAC Lung Cancer
Female (N  53) Male (N  25) Total (N  78) pa
Histologic subtype 0.7458
Non-mucinous 44 (83) 20 (80) 64 (82.1) 0.7591b
Mucinous 9 (17) 5 (20) 14 (17.9)
Stage (new) 0.3900
IA 41 (77.4) 20 (80) 61 (78.2) 0.3542b
IB 2 (3.8) 2 (8) 4 (5.1)
II/IIIA 8 (15.1) 1 (4) 9 (11.5)
IIIB/IV 2 (3.8) 2 (8) 4 (5.1)
Tumor (new) 0.8638
T1 42 (79.3) 20 (80) 62 (79.5) 1.0000b
T2 6 (11.3) 2 (8) 8 (10.3)
T3—4 5 (9.4) 3 (12) 8 (10.3)
Comorbid non-lung cancerc 0.6626
Missing 12 (—) 3 (—) 15 (—)
No 21 (51.2) 10 (45.5) 31 (49.2)
Yes 20 (48.8) 12 (54.5) 32 (50.8)
Comorbid non-lung cancerc (not non-melanoma skin) 0.5951
Missing 12 (—) 3 (—) 15 (—)
No 27 (65.9) 13 (59.1) 40 (63.5)
Yes 14 (34.1) 9 (40.9) 23 (36.5)
Comorbid lung diseased 0.0671
Missing 12 (—) 3 (—) 15 (—)
No 21 (51.2) 6 (27.3) 27 (42.9)
Yes 20 (48.8) 16 (72.7) 36 (57.1)
Comorbid non-lung diseasee 0.2192
Missing 12 (—) 3 (—) 15 (—)
No 9 (22) 8 (36.4) 17 (27)
Yes 32 (78) 14 (63.6) 46 (73)
Any symptoms present 0.3898
No 33 (62.3) 13 (52) 46 (59)
Yes 20 (37.7) 12 (48) 32 (41)
Weight loss 0.2496
Missing 1 (—) 2 (—) 3 (—) 0.2960b
No 46 (88.5) 18 (78.3) 64 (85.3)
Yes 6 (11.5) 5 (21.7) 11 (14.7)
Performance status 0.2145
0 41 (77.4) 16 (64) 57 (73.1)
1 12 (22.6) 9 (36) 21 (26.9)
Type of surgery 0.5629
Major resectionf 2 (3.8) 0 (0) 2 (2.6) 0.8002b
Lobectomy 39 (73.6) 18 (72) 57 (73.1)
Other resectiong 12 (22.6) 7 (28) 19 (24.4)
Any chemotherapy 0.5208
No 49 (92.5) 22 (88) 71 (91) 0.6741b
Yes 4 (7.5) 3 (12) 7 (9)
Chemotherapy response 0.3679
Missing 2 (—) 1 (—) 3 (—) 1.0000b
Complete 1 (50) 0 (0) 1 (25)
Progression 0 (0) 1 (50) 1 (25)
Incomplete 1 (50) 1 (50) 2 (50)
Any radiation 0.5816
No 52 (98.1) 24 (96) 76 (97.4) 0.5411b
Yes 1 (1.9) 1 (4) 2 (2.6)
The values in the parenthesis are given in percentage.
a All p values are from 2 tests unless otherwise noted.
b Fisher exact test.
c Comorbid cancer includes bladder, breast, head and neck, kidney, liver, lymphoma, melanoma, non-melanoma skin, prostate, thyroid, uterine, and other unspecified cancers.
d Comorbid lung diseases include asthma, asthmatic bronchitis, acute bronchitis, chronic bronchitis, unspecified bronchitis, chronic obstructive pulmonary disease (COPD),
emphysema, pneumonia, and other unspecified pulmonary diseases.
e Comorbid nonlung diseases include arthritis, diabetes, GI disease, heart disease, hypertension, kidney disease, liver disease, peripheral vascular disease, rheumatoid arthritis,
stroke, and other unspecified nonpulmonary diseases.
f Major resections include pneumonectomy and bilobectomy.
g Other resections include segmentectomy, wedge resection, other lung surgeries, and mets resection.
BAC, bronchioloalveolar carcinoma.
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supports the prevailing notion in the literature that most BAC
lung cancer is discovered incidentally.
We observed that 28.2% of patients with pure BAC were
never smokers. Smoking has not always been thought to be a
risk factor for BAC. However, case control studies have dem-
onstrated an association between BAC and intensity of cigarette
smoking.13,14 Between 24 and 33% of patients with BAC, 15%
of patients with adenocarcinoma, and 5% of patients with
squamous cell carcinoma are never smokers.3,13–16 However, the
exact importance of tobacco smoke exposure, active and pas-
sive, on BAC risk is not known. Possible other risk factors for
BAC that have been considered include pulmonary parenchymal
damage and scarring from pulmonary diseases, occupational
exposures, and viral infection.
A viral etiology has been suggested for BAC given its
clinical and histologic similarities to sheep pulmonary ade-
nomatosis (SPA), which is caused by the Jaagsiekte sheep
retrovirus (JSRV).17 Indeed, this etiologic conclusion was
based on the ability to produce SPA by inoculating sheep
with cell-free lung secretions of infected animals18 and with
TABLE 4. Comparison of Survival Between Patients with Pure and Non-Pure Bronchioloalveolar
Carcinoma with no Other Non-BAC Lung Cancer
Overall
(n  256)
Pure BAC
(N  78, 30.5%)
Non-Pure BAC
(N  178, 69.5%) p
Number of events (deaths) 109 (42.6%) 15 (19.2%) 94 (52.8%)
Median survival (yr) 7.59 10.41 4.30
Overall postdiagnosis survival
6 mo 93.7% (90.7, 96.7) 96.1% (91.9, 100) 92.6% (88.8, 96.6) 0.0001
1 yr 89.2% (85.4, 93.1) 94.8% (90.0, 99.9) 86.7% (81.8, 91.9) 0.0001a
2 yr 77.5% (72.4, 82.9) 93.5% (88.1, 99.2) 70.4% (63.8, 77.6) 0.0001b
3 yr 71.8% (66.3, 77.7) 92.1% (86.2, 98.4) 62.6% (55.6, 70.5)
4 yr 63.8% (57.8, 70.4) 85.4% (77.3, 94.3) 54.0% (46.7, 62.4)
5 yr 57.9% (51.5, 64.9) 83.5% (74.9, 93.1) 46.4% (38.9, 55.3)
6 yr 54.4% (47.8, 61.8) 81.3% (72.1, 91.7) 42.2% (34.6, 51.5)
7 yr 53.3% (46.7, 60.9) 81.3% (72.1, 91.7) 40.8% (33.1, 50.3)
8 yr 48.0% (40.5, 56.8) 77.0% (65.6, 90.4) 35.5% (27.2, 46.2)
9 yr 42.2% (33.8, 52.8) 69.3% (53.4, 90.1) 31.1% (22.6, 42.9)
10 yr 38.7% (29.2, 51.3) 69.3% (53.4, 90.1) 26.7% (17.2, 41.4)
a Follow-up time was capped at 10 yr, and all deaths after 10 yr were censored (n  1).
b Follow-up time was capped at 5 yr, and all deaths after 5 yr were censored (n  23).
BAC, bronchioloalveolar carcinoma.
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FIGURE 1. Survival by old (1999) stage (A) and new (2009) stage (B) for 78 patients with pure bronchioloalveolar carcinoma
and no other non-BAC lung cancer.
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full length JSRV proviral clones transfected in vivo into
newborn lambs.19 JSRV has also been demonstrated in epi-
thelial tumor cells by immunohistochemical staining,20 and
the genomic sequence of JSRV has been derived from viral
particle RNA purified from lung secretions of ovine pulmo-
nary adenocarcinoma (OPA)-affected sheep.21,22 The similar-
ity of clinical course and histologic morphology between
SPA and human BAC, particularly mucinous BAC, has raised
interest on the possible role of JSRV in the development of
human lung carcinoma. In 1994, researchers suggested that
JSRV may be related to the human BAC.23 These findings
were followed by an immunohistochemical study showing
that 30% of BAC and 26% of typical adenocarcinomas
stained positively with antiserum against the JSRV capsid
protein.24 Although some researchers reported the pres-
ence of JSRV in tissue sections from human BAC depends
on patients’ geographical origin,25 molecular studies using
polymerase chain reaction and reverse transcriptase poly-
merase chain reaction techniques could not confirm this
finding.26 JSRV continues to be an interesting model for
BAC although there is insufficient evidence to support a
causal association.
Our study has several notable strengths. First, the pa-
tients in this study are a subset of patients with lung cancer
who have prospectively enrolled at diagnosis; all patients
with a diagnosis of lung cancer are invited to participate,
which eliminates selection bias. Second, the diagnosis of
BAC was confirmed by review of tumor slides by a pulmo-
nary pathologist. This is particularly important given that
many BAC epidemiology studies do not include central
pathologic review, thus making it difficult for clinicians
and researchers to interpret the results. Third, detailed
information on each study patient was available for anal-
ysis including sites of other cancers for patients who had a
cancer other than BAC.
One of the limitations of this study relates to a potential
referral bias. We have minimized the referral bias by includ-
ing both patients referred to Mayo Clinic, Rochester, and
patients who live in the surrounding community. A second
limitation is that most included patients were white. A third
limitation relates to missing data for some clinical informa-
tion. However, we do not believe that the missing data had
any particular pattern that can be related to significant impact
on the study results.
Our study provides new information on the clinical
characteristics and excellent prognosis of patients with pure
BAC. Because the new pathology and staging systems affect
epidemiology, treatment, and life expectancy for BAC, they
have important implications for researchers, clinicians, and
patients.
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